Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol

European Journal of Contraception and Reproductive Health Care

Volumn 15, Issue 5, 2010, Pages 314-325

  Duijkers, Ingrid J M ^a   Klipping, Christine ^a   Grob, Paul ^a   Korver, Tjeerd ^a  

^a NONE

Author keywords

17 oestradiol; Contraceptive efficacy; Nomegestrol acetate; Oral contraceptive; Ovulation inhibition

Indexed keywords

DROSPIRENONE; ESTRADIOL; ETHINYLESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; NOMEGESTROL ACETATE; PROGESTERONE;

ABDOMINAL PAIN; ACNE; ADULT; APPENDICITIS; ARTICLE; BREAST AUGMENTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MASTALGIA; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; NAUSEA; ORAL CONTRACEPTION; OVARY FOLLICLE; OVARY FUNCTION; OVULATION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UTERINE CERVIX MUCUS; WEIGHT GAIN;

ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; ESTRADIOL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MEGESTROL; MENSTRUAL CYCLE; NORPREGNADIENES; OVULATION; PROGESTERONE; YOUNG ADULT;

EID: 77957309020     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2010.504313     Document Type: Article

References (26)

1. United Nations Department of Economic and Social Affairs Population Division. World contraceptive use 2007. Accessed 5 August 2009 from: http://www.un.org/esa/population/publications/contraceptive2007/ contraceptive-2007-tablepdf
2. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low-and lower-dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999;60:321-9.
3. Blackburn RD, Cunkelman JA, Zlidar VM. Oral contraceptives - an update. Baltimore: Johns Hopkins University School of Public Health, Population Information Program; Spring 2000.
4. Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998;57:211-30.
5. Hoffmann H, Moore C, Zimmermann H, et al. Approaches to the replacement of ethinylestradiol by natural 17 beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol 1998;50:458-64.
6. Calaf i Alsina J. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care 2010;15:1-3.
7. Hirvonen E, Allonen H, Anttila M, et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995;21:27-32.
8. Koetsawang S, Mandlekar AV, Krishna UR, et al. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception. Contraception 1980;21:445-59.
9. Wenzl R, Coelingh Bennink H, van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993;60:616-9.
10. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78.
11. Kuhl H. Pharmacology of estrogens and progestogens: Influence of different routes of administration. Climacteric 2005;8(Suppl. 1):3-63.
12. Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239-46.
13. Ezan E, Benech H, Bucourt R, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993;46:507-14.
14. Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 1999;84:4191-6.
15. Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987;94:1199-204.
16. Barbosa IC, Maia H, Jr, Coutinho E, et al. Effects of a single Silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. Contraception 2006;74:492-7.
17. Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991;44:599-605.
18. Dorangeon P, Thomas JL, Choisy H, et al. Effects of nomegestrol acetate on carbohydrate metabolism. Diabetes Metab 1993;19:441-5.
19. Insler V, Melmed H, Eichenbrenner I, et al. The cervical score. A simple semiquantitative method for monitoring the menstrual cycle. Int J Gynaecol Obstet 1972;10:223-8.
20. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
21. Landgren BM, Diczfalusy E. Hormonal effects of the 300 microgram norethisterone (NET) minipill. I. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception 1980;21:87-113.
22. Milsom I, Korver T. Ovulation incidence with oral contraceptives: A literature review. J Fam Plann Reprod Health Care 2008;34:237-46.
23. Serfaty D, Christin Maitre S, Ochsenbein E, et al. Comparison of two regimens of new monophasic oral contraceptive combining 17 beta-estradiol and nomegestrol acetate. Poster (Abstract 738. P) presented at XIX FIGO World Congress of Gynecology and Obstetrics, Cape Town, South Africa, 4-9 October 2009.
24. Korver T, Goorissen E, Guillebaud J. The combined oral contraceptive pill: What advice should we give when tablets are missed? Br J Obstet Gynaecol 1995;102:601-7.
25. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511-8.
26. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl. 1): S7-S16.